secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001493152-23-016388
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell Therapeutics Q1 net loss $4.4M, cash $46.8M; OpRegen phase 2a enrolling
--------------------------------------------------------------------------------

- Revenue $2.4M, down 54% YoY from $5.2M due to lower Roche collaboration revenue.
- Net loss improved to $4.4M ($0.03/share) from $7.1M ($0.04/share) in Q1 2022.
- Cash equivalents and marketable securities $46.8M; expected to fund operations into Q3 2024.
- OpRegen Phase 2a for GA secondary to AMD continues enrolling; new sites expected in 2023.
- OPC1 granted US patent expiring no earlier than 2040; Type B meeting with FDA planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000149315223016388/0001493152-23-016388-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000149315223016388/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-016388

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer